WD
Therapeutic Areas
Metagenomi Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MGX-001 | Severe Hypertriglyceridemia (APOC3 Knockout) | Preclinical |
| MGX Platform (CAST) | Hemophilia A (Factor VIII Gene Insertion) | Preclinical |
| MGX Platform (Nuclease) | Undisclosed CNS Target | Preclinical |
| MGX Platform (Base Editor) | Undisclosed Therapeutic Application | Preclinical |
| MGX Platform (Compact Nuclease) | Undisclosed In Vivo Application | Preclinical |
Leadership Team at Metagenomi
JI
Jian Irish, PhD, MBA
President and CEO
PW
Pamela Wapnick, MBA
CFO
MW
Matthew Wein, JD
General Counsel, Compliance Officer, Head of BD & L & Corporate Secretary
AB
Alan Brooks, PhD
SVP, Research
KK
Katalin Kauser, PhD, MD, Sc.D
SVP, Translational Biology
ML
Mark Leonard, PhD
SVP, Technical Operations
KS
Kapil Saxena, MD, MS
VP, Clinical Development
EB
Eric Bjerkholt, MBA
Board Member